South Korean media: China's pharmaceutical and biotechnology industry competitiveness has surpassed the EU and even the United States!
On September 1, South Korean media NEWSPIM published an article stating that assessments suggest China's pharmaceutical and biotechnology industry competitiveness not only exceeds the EU but has also surpassed the United States.
Recently, the UK's Financial Times reported that global major pharmaceutical companies are increasingly dependent on Chinese biotechnology companies. "Chinese pharmaceutical and biotechnology companies are restructuring the global biotechnology industry."
According to the global pharmaceutical company candidate drug licensing data for the first half of this year, Chinese pharmaceutical companies accounted for 18% and 32% respectively in the number of global transactions and total transaction amounts, setting a new historical high for China in terms of the number of drug licenses and transaction amounts.
This means that the candidate substances being developed by Chinese pharmaceutical companies have strong competitiveness, and China's biotech competitiveness has risen to a global leading level.
Mark McClellan, a professor at Duke University and former head of the U.S. Food and Drug Administration (FDA), said, "China's innovation in biotechnology is ahead of the United States."
Bloomberg also reported, "The pace of progress in China's biotechnology field is as fast as its achievements in artificial intelligence and electric vehicles. It has not only surpassed the EU but also the United States." Bloomberg estimates that the number of new drugs entering the research and development stage in China last year surged to 1,250, far exceeding the EU and comparable to the 1,440 in the United States.
Axios, an American media outlet, reported, "China is rising as a key country in global drug development," "Last year, the number of clinical trials registered on the World Health Organization's clinical trial registration platform in China reached 7,100, surpassing the United States, which had 6,000."
Daniel Chancellors, vice president of the U.S. pharmaceutical and biotechnology consulting company Norstella, said, "Judging from the number of new drugs launched, it is not surprising to claim that China will surpass the United States in the coming years."
At the same time, in May, Chinese pharmaceutical company Sanbio Pharmaceutical signed a large licensing contract, becoming the focus of media attention. The licensor was the global pharmaceutical company Pfizer, with a contract amount of $6 billion, including a $120 million upfront payment and $480 million in milestone payments.
Original: www.toutiao.com/article/1842065112289288/
Statement: This article represents the personal views of the author.